FOR IMMEDIATE RELEASE [HCM City/Vietnam, 23rd Sep.] – P&Y Livestock Services Co., Ltd. (CÔNG TY TNHH DỊCH VỤ CHĂN NUÔI P&Y) today announced an upcoming high-profile seminar aimed at livestock and veterinary professionals, titled: "Disease Situation in Livestock and Poultry in 2025 and Updates on Porcine Circovirus (PCV) in Pigs and Salmonella in Poultry."
The seminar is designed to equip industry participants with the most current epidemiological data, virological research, and effective disease control strategies to tackle pressing challenges in animal farming, particularly those related to antimicrobial resistance.
Key Topics and Speaker Lineup:
-
Bacterial Diseases and Antimicrobial Resistance Trends: Ms. Nguyễn Thị Phương Bình, M.Sc., Director of P&Y, will present the current situation of bacterial diseases and updates on antibiotic resistance in pigs and poultry.
-
Analysis of Viral Diseases and Emerging Issues: Prof. Nguyễn Ngọc Hải, Ph.D., from Nong Lam University, will provide an in-depth analysis of the status and newly emerging problems related to viral diseases in pigs and poultry.
-
Salmonella in Poultry Management: Ms. Nguyễn Thị Thu Năm, M.Sc., Director of the Veterinary Hospital at Nong Lam University, will share detailed insights into the prevention and control of Salmonella in poultry.
-
CIRCOQ Vaccine Promotion and Core Technical Insights from REBER GENETICS: Dr. Chia-Jung Frank Chang, Ph.D., CTO of REBER GENETICS, will present the "CIRCOQ PCV2 targeted subunit vaccine: Effective control tool of porcine circovirus in the field," and share promotion strategies and core technical information regarding the vaccine.
-
Latest PCVs Research Updates: Prof. Hải will also deliver the newest research updates on Porcine Circovirus (PCVs) in pigs.
P&Y company warmly invites industry professionals, veterinarians, farm managers, and anyone interested in animal disease control to register and attend this critical seminar.
And Reber Genetics Co., Ltd. was honored to be invited to give a lecture in this event.
To share the innovation perspective on PCV2 subunit vaccine developing strategy.